All In MedTech

Device Trial Radar · NCT03465904

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

A Phase III Randomized, Double-blind, Sham-controlled Trial of e-TNS for the Acute Treatment of Migraine (The TEAM Study)

Last checked: Nov 19, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 607 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

607

Actual

Start

Apr 10, 2018

Primary completion

Jan 11, 2019

Study completion Jan 11, 2019

Sponsor

Lead sponsor
Cefaly TechnologyNot on our public-company list
Sponsor type
Industry
First posted
Mar 14, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This randomized, double-blind, sham-controlled trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device.

Conditions

  • Migraine

Interventions

  • Verum Cefaly® Abortive Program deviceDevice

    The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.

  • Sham Cefaly® Abortive Program deviceDevice

    The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Freedom at 2 HoursTime frame: 2 hours
  2. Most Bothersome Migraine-associated Symptom Freedom at 2 HoursTime frame: 2 hours

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Consortium

    Tempe, Arizona

  • Pharmacology Research Institute

    Encino, California

  • Yale University

    New Haven, Connecticut

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.